• Patients report adalimumab for uveitis improves quality of life

    3 monthes ago - By Healio

    A post hoc analysis of pivotal multicenter trials evaluating adalimumab as a treatment for uveitis showed meaningful patient-reported improvement in visual functioning and vision-related quality of life. Adalimumab is an anti-inflammatory drug approved for the treatment of noninfectious intermediate uveitis, posterior uveitis and panuveitis. It was tested in the VISUAL-1 and VISUAL-2 phase 3 placebo-controlled trials in patients with, respectively, active and inactive uveitis previously treated with oral corticosteroid therapy. In the trials, adalimumab showed efficacy in lowering the risk...
    Read more ...